FibroBiologics, Inc.

NasdaqGM:FBLG Stock Report

Market Cap: US$80.1m

FibroBiologics Management

Management criteria checks 2/4

FibroBiologics' CEO is Pete O’Heeron, appointed in Apr 2021, has a tenure of 3.67 years. total yearly compensation is $4.29M, comprised of 14% salary and 86% bonuses, including company stock and options. directly owns 17.04% of the company’s shares, worth $13.64M. The average tenure of the management team and the board of directors is 2 years and 3.7 years respectively.

Key information

Pete O’Heeron

Chief executive officer

US$4.3m

Total compensation

CEO salary percentage14.0%
CEO tenure3.7yrs
CEO ownership17.0%
Management average tenure2yrs
Board average tenure3.7yrs

Recent management updates

Recent updates

Here's Why We're Watching FibroBiologics' (NASDAQ:FBLG) Cash Burn Situation

Nov 14
Here's Why We're Watching FibroBiologics' (NASDAQ:FBLG) Cash Burn Situation

CEO Compensation Analysis

How has Pete O’Heeron's remuneration changed compared to FibroBiologics's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$18m

Jun 30 2024n/an/a

-US$19m

Mar 31 2024n/an/a

-US$23m

Dec 31 2023US$4mUS$600k

-US$19m

Sep 30 2023n/an/a

-US$11m

Jun 30 2023n/an/a

-US$10m

Mar 31 2023n/an/a

-US$9m

Dec 31 2022US$922kUS$600k

-US$5m

Compensation vs Market: Pete's total compensation ($USD4.29M) is above average for companies of similar size in the US market ($USD650.00K).

Compensation vs Earnings: Pete's compensation has increased whilst the company is unprofitable.


CEO

Pete O’Heeron (60 yo)

3.7yrs

Tenure

US$4,286,123

Compensation

Mr. Peter O'Heeron, MSHA, also known as Pete, is the Founder, Chairperson & Chief Executive Officer at FibroBiologics, Inc. (Formerly, FibroBiologics LLC) since April 2021. Mr. O’Heeron is also the founder...


Leadership Team

NamePositionTenureCompensationOwnership
Peter O’Heeron
Founder3.7yrsUS$4.29m17.04%
$ 13.6m
Robert Hoffman
Interim CFO & Directorless than a yearUS$388.54k0.022%
$ 17.3k
Hamid Khoja
Chief Scientific Officer3.3yrsUS$1.31m0.032%
$ 26.0k
Ruben Garcia
General Counselless than a yearno datano data

2.0yrs

Average Tenure

56yo

Average Age

Experienced Management: FBLG's management team is considered experienced (2 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Peter O’Heeron
Founder3.7yrsUS$4.29m17.04%
$ 13.6m
Robert Hoffman
Interim CFO & Director3.7yrsUS$388.54k0.022%
$ 17.3k
Richard Cilento
Independent Director3.7yrsUS$376.54k0.27%
$ 215.4k
Elizabeth Shpall
Scientific Advisory Board Memberno datano datano data
Matthew Link
Independent Director3.7yrsUS$379.54k0.022%
$ 17.3k
Victoria Niklas
Independent Director3.7yrsUS$381.54k0.022%
$ 17.3k
Stacy Coen
Independent Director3.4yrsUS$384.54k0.022%
$ 17.3k
Claudia Lucchinetti
Scientific Advisory Board Memberno datano datano data
Kate Rubins
Scientific Advisory Board Memberno datano datano data
Neil Bhowmick
Scientific Advisory Board Memberno datano datano data
S. Carmichael
Scientific Advisory Board Memberno datano datano data

3.7yrs

Average Tenure

58yo

Average Age

Experienced Board: FBLG's board of directors are considered experienced (3.7 years average tenure).


Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/26 07:37
End of Day Share Price 2024/12/26 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

FibroBiologics, Inc. is covered by 4 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jason KolbertD. Boral Capital LLC.
Matthew CaufieldH.C. Wainwright & Co.
Michael OkunewitchMaxim Group